Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
The respective benefits of high and low doses of dexamethasone (DXM) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute respiratory failure (ARF) are controversial, with two...
Source: Annals of Intensive Care - Category: Intensive Care Authors: Chevret Sylvie, Bouadma Lila, Dupuis Claire, Burdet Charles and Timsit Jean-Fran çois Tags: Research Source Type: research
More News: Clinical Trials | Coronavirus | COVID-19 | Dexamethasone | Intensive Care | Respiratory Medicine | SARS